Current Hematologic Malignancy Reports

, Volume 7, Issue 3, pp 216–220

The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways

Lymphomas (J Armitage and P McLaughlin, Section Editors)

DOI: 10.1007/s11899-012-0127-0

Cite this article as:
Kenkre, V.P. & Kahl, B.S. Curr Hematol Malig Rep (2012) 7: 216. doi:10.1007/s11899-012-0127-0


It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton’s tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.


Non-Hodgkin lymphomaB cell receptorTargeted therapySpleen tyrosine kinase (Syk)Bruton’s tyrosine kinase (BTK)phosphoinositide 3-kinase (PI3K)

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.University of WisconsinMadisonUSA
  2. 2.University of WisconsinMadisonUSA
  3. 3.Department of Medicine, Division of Hematology/OncologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  4. 4.UW Carbone Cancer CenterMadisonUSA